Pacific Biosciences of California (PACB) News Today → Wall Street legend who predicted 2021 tech crash issues new warning (From Chaikin Analytics) (Ad) Free PACB Stock Alerts $2.14 -0.08 (-3.60%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 11:27 AM | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Stock Price Down 5.6% on Analyst DowngradePacific Biosciences of California (NASDAQ:PACB) Trading Down 5.6% Following Analyst DowngradeMay 15 at 10:32 AM | marketbeat.comMorgan Stanley Trims Pacific Biosciences of California (NASDAQ:PACB) Target Price to $4.00Morgan Stanley decreased their price objective on Pacific Biosciences of California from $10.00 to $4.00 and set an "equal weight" rating for the company in a report on Wednesday.May 15 at 9:45 AM | prnewswire.comAmbry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare DiseasesMay 15 at 8:12 AM | marketbeat.comFY2024 EPS Estimates for Pacific Biosciences of California, Inc. Raised by Cantor Fitzgerald (NASDAQ:PACB)Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for shares of Pacific Biosciences of California in a research report issued on Monday, May 13th. Cantor Fitzgerald analyst R. OsboMay 15 at 5:27 AM | americanbankingnews.comPacific Biosciences of California (NASDAQ:PACB) Upgraded at StockNews.comMay 15 at 3:54 AM | americanbankingnews.comPiper Sandler Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $2.00May 15 at 12:09 AM | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Lifted to "Sell" at StockNews.comStockNews.com upgraded Pacific Biosciences of California to a "sell" rating in a report on Tuesday.May 14 at 5:05 PM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Liquidia Technologies (LQDA) and Pacific Biosciences (PACB)May 14 at 1:07 PM | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Shares Gap Up to $1.93Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up to $1.93May 13 at 5:12 PM | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Shares Up 11.9%Pacific Biosciences of California (NASDAQ:PACB) Trading Up 11.9%May 13 at 9:23 AM | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Given New $2.00 Price Target at Piper SandlerPiper Sandler dropped their target price on Pacific Biosciences of California from $6.50 to $2.00 and set a "neutral" rating for the company in a research report on Monday.May 13 at 6:46 AM | americanbankingnews.comBarclays Trims Pacific Biosciences of California (NASDAQ:PACB) Target Price to $2.00May 13 at 4:55 AM | marketbeat.comVictory Capital Management Inc. Acquires 442,250 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)Victory Capital Management Inc. lifted its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 67.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,094,724 shares of the biotechnMay 11, 2024 | finance.yahoo.comPacific Biosciences of California First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | markets.businessinsider.comOptimistic Outlook: Buy Rating on Pacific Biosciences Amidst Turnaround Efforts and Long-term Growth PotentialMay 10, 2024 | insidermonkey.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2024 Earnings Call TranscriptMay 9, 2024 | seekingalpha.comPacific Biosciences of California, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 9, 2024 | markets.businessinsider.comPacific Biosciences Of California, Inc. Q1 Loss Decreases, Beats EstimatesMay 9, 2024 | prnewswire.comPacBio Announces First Quarter 2024 Financial ResultsMay 8, 2024 | markets.businessinsider.comPacific Biosciences of California is about to announce its earnings — here's what to expectMay 7, 2024 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Trading Down 5.3%Pacific Biosciences of California (NASDAQ:PACB) Shares Down 5.3%May 6, 2024 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Trading 10.1% Higher Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 10.1%May 5, 2024 | americanbankingnews.comPacific Biosciences of California (NASDAQ:PACB) Shares Gap Up to $1.76May 4, 2024 | marketbeat.comVestmark Advisory Solutions Inc. Invests $4.85 Million in Pacific Biosciences of California, Inc. (NASDAQ:PACB)Vestmark Advisory Solutions Inc. bought a new stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 494,790 shares of the biotechnology company's stock, valuMay 2, 2024 | tmcnet.comMedGenome announces de novo Genome Assembly and Annotation Grant winners for 2024April 30, 2024 | bizjournals.comLatest biotech cuts hit pioneering DNA sequencing company, Verily's eye-focused joint ventureApril 29, 2024 | marketbeat.comPacific Biosciences of California (PACB) Scheduled to Post Quarterly Earnings on TuesdayPacific Biosciences of California (NASDAQ:PACB) will be releasing earnings on Tuesday, April 30, Yahoo Finance reports.April 23, 2024 | msn.comJP Morgan Downgrades Pacific Biosciences of California (PACB)April 23, 2024 | marketbeat.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fifteen ratings firms that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold recommeApril 22, 2024 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Lowered to "Neutral" at JPMorgan Chase & Co.JPMorgan Chase & Co. cut shares of Pacific Biosciences of California from an "overweight" rating to a "neutral" rating in a research note on Monday.April 18, 2024 | msn.comPacBio cut to Neutral at Goldman Sachs after guidance cutApril 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB) and Eli Lilly & Co (LLY)April 18, 2024 | msn.comPacific Biosciences of California (PACB) Price Target Decreased by 18.15% to 9.01April 17, 2024 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Price Target Cut to $2.50 by Analysts at TD CowenTD Cowen cut their price target on shares of Pacific Biosciences of California from $12.00 to $2.50 and set a "buy" rating for the company in a research note on Wednesday.April 17, 2024 | baystreet.caMid-Week Wednesday's Most Active BuysApril 16, 2024 | finanznachrichten.dePacific Biosciences of California, Inc.: PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue GuidanceApril 16, 2024 | investorplace.comThe Cathie Wood Stock Shuffle: 4 Names She's Loving, 3 She's LeavingApril 16, 2024 | msn.comPacBio falls after issuing guidance below expectationsApril 16, 2024 | markets.businessinsider.comPacBio Q1 Prel. Revenue Nearly Flat, Annual Revenue Outlook Below View; Stock DownApril 16, 2024 | finance.yahoo.comPacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue GuidanceApril 13, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Has $9.09 Million Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB)Mirae Asset Global Investments Co. Ltd. decreased its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 35.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 926,9April 12, 2024 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Hits New 52-Week Low at $3.15Pacific Biosciences of California (NASDAQ:PACB) Reaches New 1-Year Low at $3.15April 10, 2024 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Stock Price Down 8.3% Following Analyst DowngradePacific Biosciences of California (NASDAQ:PACB) Stock Price Down 8.3% on Analyst DowngradeApril 9, 2024 | marketbeat.comMoody Aldrich Partners LLC Makes New Investment in Pacific Biosciences of California, Inc. (NASDAQ:PACB)Moody Aldrich Partners LLC bought a new stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 418April 9, 2024 | fool.caNASDAQ:PACB (Pacific Biosciences Of California)April 8, 2024 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Shares Gap Up to $3.35Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up to $3.35April 4, 2024 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Trading 4.5% Higher Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 4.5%April 3, 2024 | tmcnet.comSaviynt Recognized on Inc. Magazine's List of the Pacific Region's Fastest-Growing Private CompaniesApril 2, 2024 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Hits New 52-Week Low at $3.42Pacific Biosciences of California (NASDAQ:PACB) Hits New 12-Month Low at $3.42March 29, 2024 | marketbeat.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Recommendation of "Moderate Buy" by BrokeragesPacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen analysts that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating and eight have assigned a Get Pacific Biosciences of California News Delivered to You Automatically Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street legend who predicted 2021 tech crash issues new warning (Ad)People around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history. Watch his stock warning right here, 100% free of charge PACB Media Mentions By Week PACB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PACB News Sentiment▼0.300.55▲Average Medical News Sentiment PACB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PACB Articles This Week▼264▲PACB Articles Average Week Get Pacific Biosciences of California News Delivered to You Automatically Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EYPT News Today QTRX News Today NAUT News Today LAB News Today AKYA News Today CTKB News Today HBIO News Today SEER News Today ALEC News Today STTK News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PACB) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsGold Set to EXPLODE!Gold Safe Exchange"The Biggest Drug Ever" Is ComingBehind the MarketsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
